Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;11(2):543-553.
doi: 10.1007/s13555-021-00499-8. Epub 2021 Mar 5.

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Martina Kojanova  1 , Petra Cetkovska  2 , Daniela Strosova  3 , Jorga Fialova  4 , Petr Arenberger  5 , Tomas Dolezal  3 , Spyridon Gkalpakiotis  5 ; BIOREP Study Group
Collaborators, Affiliations

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Martina Kojanova et al. Dermatol Ther (Heidelb). 2021 Apr.

Abstract

Introduction: The study aimed to evaluate the real-world effectiveness of adalimumab as well as investigate the persistence of treatment and identify factors, which may affect it.

Methods: More than 1150 patients (4363.1 patient-years) with psoriasis who had been treated with adalimumab since the start of the BIOREP registry in the Czech Republic were included in this analysis. Treatment effectiveness was defined as improvement in Psoriasis Area and Severity Index (PASI). The analysis was performed during the years 2005 and 2018. Patients were on on-label dose.

Results: After 12 and 96 months of therapy, 84% and 88% of patients had a 75% reduction in PASI score from baseline, respectively. Drug survival was analyzed according to the number of previous biological therapies, and results showed 75% and 58.1% survival rate for biologically naïve patients in the 20th and 80th month of treatment, respectively. The negative predictors of adalimumab survival were the female gender, obesity, baseline PASI score and the number of previous biological therapies.

Conclusions: Baseline factors including PASI, number of previous biological therapies, and sex were associated with shorter adalimumab survival. This long-term study shows that adalimumab is effective and has high treatment persistence.

Keywords: Adalimumab; BIOREP; Long-term effectiveness; Persistence of treatment; Psoriasis; Registries.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment response based on PASI
Fig. 2
Fig. 2
Survival probability on biological treatment according to treatment lines
See this image and copyright information in PMC

References

    1. Boehncke W-H, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7. - DOI - PubMed
    1. Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22(8 Suppl):s225–237. - PubMed
    1. Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatol Basel Switz. 2018;234(1–2):1–12. - PubMed
    1. Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458. doi: 10.1111/bjd.17738. - DOI - PubMed
    1. Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatol Treat. 2019;30(3):227–236. doi: 10.1080/09546634.2018.1506084. - DOI - PubMed

LinkOut - more resources